Emile Voest
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.
Back to newsMore news
Whole Genome Sequencing feasible in clinical practice
Interim WIDE analysis gives researchers more confidence in a positive outcome. On 21 September 2020, Dr. Kim Monkhorst, who is a …
Erasmus MC Cancer Institute introduces comprehensive DNA testing for CUP cancer patients in EMBRAZE region
The Erasmus MC Cancer Institute has started using comprehensive DNA testing for carcinoma of unknown primary (CUP) cancer patients in …
Actionable metastatic cancer genome is remarkably stable over time, despite treatment with drugs
A one-time analysis of the entire tumor DNA is almost always sufficient to find all DNA errors that may be …
The complete DNA test is an additional tool to help us discover the origin of the cancer in patients with CUP, often enabling us to identify this primary tumor. In addition, the test often reveals new options for targeted treatment.